Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $11.05, for a total value of $22,100.00. Following the sale, the president now directly owns 2,940,467 shares in the company, valued at approximately $32,492,160.35. This trade represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Gyre Therapeutics Stock Down 0.4 %

GYRE stock traded down $0.04 during midday trading on Thursday, reaching $10.66. The company had a trading volume of 112,081 shares, compared to its average volume of 74,347. Gyre Therapeutics, Inc. has a 1-year low of $8.26 and a 1-year high of $30.40. The stock has a 50 day moving average price of $12.93 and a 200-day moving average price of $12.59.

Hedge Funds Weigh In On Gyre Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in GYRE. Charles Schwab Investment Management Inc. increased its stake in Gyre Therapeutics by 392.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after acquiring an additional 90,557 shares during the last quarter. Rhumbline Advisers acquired a new stake in Gyre Therapeutics in the second quarter valued at about $123,000. Renaissance Technologies LLC bought a new position in Gyre Therapeutics in the second quarter valued at about $166,000. WINTON GROUP Ltd acquired a new position in Gyre Therapeutics during the second quarter worth about $220,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Gyre Therapeutics in the second quarter worth about $218,000. 23.99% of the stock is currently owned by institutional investors and hedge funds.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.